A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

NCT00851409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Genetic Disorders
Hereditary Angioedema

Interventions

DRUG: Recombinant Human C1 Inhibitor

Sponsor

Pharming Technologies B.V.